Assertio Therapeutics, Inc. buy Subdi
Start price
11.01.16
/
50%
€13.29
Target price
03.05.17
€25.26
Performance (%)
-25.39%
End price
03.05.17
€9.91
Summary
This prediction ended on 03.05.17 with a price of €9.91. The price of Assertio Therapeutics, Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -25.39%. Subdi has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Assertio Therapeutics, Inc. | -2.667% | -2.667% | -87.813% | -92.074% |
iShares Core DAX® | 1.195% | 2.111% | 17.166% | 16.919% |
iShares Nasdaq 100 | 3.220% | -1.375% | 22.801% | 33.740% |
iShares Nikkei 225® | 1.858% | 0.888% | 10.064% | -0.682% |
iShares S&P 500 | 2.168% | 0.612% | 22.739% | 38.274% |
Comments by Subdi for this prediction
In the thread Assertio Therapeutics, Inc. diskutieren
Subdi stimmt der Buy-Einschätzung von datca zu
Einer von drei aktuellen Biotech-Picks von Bret Jensen
Subdi stimmt am 11.01.2016 der Buy-Einschätzung von datca mit dem Kursziel 45$ zu.
Überschrift: Aussichtsreich, auch ohne Übernahme durch Horizon Pharma!
(Stop Loss Kurs erreicht)